Streetbeat News

Products Services

KROS

Keros Therapeutics presented new clinical data from its Phase 2 trials of elritercept at the ASH Annual Meeting, focusing on treatments for myelodysplastic syndromes and myelofibrosis.

Portfolio Pulse from

December 10, 2024 | 12:45 am

COIN

Coinbase Global (COIN) is capitalizing on the increasing optimism and support for Bitcoin and other cryptocurrencies, despite Bitcoin's recent slide below $100,000.

Portfolio Pulse from

December 10, 2024 | 12:15 am

ASAN

Asana's AI Studio has driven a significant stock increase, and its stickiness is expected to boost growth. Favorable rate cuts may further enhance customer adoption.

Portfolio Pulse from

December 10, 2024 | 12:00 am

TMUS

T-Mobile US, Inc. CEO Mike Sievert presented at the UBS Global Media and Communications Conference, discussing the company's strategies and outlook.

Portfolio Pulse from

December 09, 2024 | 11:45 pm

MBLY

Mobileye CEO Amnon Shashua discusses the company's growth drivers and strategies during an investor day event, highlighting the importance of the Chinese market.

Portfolio Pulse from

December 09, 2024 | 11:00 pm

TCRX

TScan Therapeutics will present updated data from its ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting. The trial shows promising results with event-free survival favoring the treatment arm.

Portfolio Pulse from

December 09, 2024 | 11:00 pm

LLY

Eli Lilly's Phase 3 trial results for Jaypirca® (pirtobrutinib) show a significant reduction in disease progression risk for chronic lymphocytic leukemia patients previously treated with BTK inhibitors. The study demonstrated a 46% reduction in risk compared to other treatments, with a median time to next treatment or death of 23.9 months.

Portfolio Pulse from

December 09, 2024 | 11:00 pm

GILD

Kite, a Gilead Company, announced that its CAR T-cell therapy, Yescarta, showed durable response and long-term survival in patients with relapsed/refractory non-Hodgkin lymphomas after five years, according to a Phase 2 study presented at ASH 2024.

Portfolio Pulse from

December 09, 2024 | 11:00 pm

BMY

Bristol Myers Squibb presented significant progress in its cell therapy portfolio at ASH 2024, showcasing long-term survival data and results from its expanding pipeline.

Portfolio Pulse from

December 09, 2024 | 11:00 pm

REGN

Odronextamab shows promising results in treating follicular lymphoma, with complete responses in all patients in the Phase 3 OLYMPIA-1 trial. This highlights its potential in earlier treatment lines and other lymphoma types.

Portfolio Pulse from

December 09, 2024 | 11:00 pm